Clinical Trial Research

Sponsor: Novo Nordisk

Protocol: NN9535-4321 (Phase-3b) (Non-dialysis)

A randomized Double-blind, Event – driven, Placebo controlled, multicenter study of the Effect of Semaglutide versus placebo on the progression of renal impairment in subjects with type 2 diabetes and chronic kidney disease. Open for Enrollment:

Sponsor: Cara Therapeuticsf

Protocol: ID-080A305 (Phase-3) (Non-dialysis)

Multi-center, Double-blinded, randomized study with aprocitentan in subjects with uncontrolled blood pressure and chronic kidney disease stage 3 or 4.

Sponsor: Akebia Therapeutics

Protocol: AKB-6548-CI (Phase-3) (Non-dialysis)

A Randomized, Open-label, Active-controlled study evaluating the Efficacy and Safety of Oral Vadadustat for the correction of Anemia in subjects with non -dialysis and dialysis dependent Chronic Kidney Disease.

Sponsor: Cara Therapeutics

Protocol: CR845-CLIN3101, 3102 and 3103 (Phase 3) (Dialysis)

Sponsor: Relypsa, Inc.

Protocol: NCT03888066 (Phase 3)

This study is for Heart failure patients who have Hyperkalemia, EF factor <35% , must be on RAAS treatment and have recent History of Hospitalization due to Heart failure with in 12 months.

A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal, Parallel Group Study of Patiromer for the Management of Hyperkalemia in Subjects Receiving Renin-Angiotensin-Aldosterone System Inhibitor (RAASi) Medications for the Treatment of Heart Failure .